Inclusion Criteria:

1. Male or female patients aged 18 years or older.

2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

3. Diagnosis of a nonhematologic malignancy for which standard curative or
lifeprolonging treatment does not exist or is no longer effective.

4. Radiographically or clinically evaluable tumor; however, measurable disease is not
required for participation in this study (eg, patients with pleural effusion or
ascites).

5. Female patients who:

- Are postmenopausal for at least 1 year before the screening visit, or

- Are surgically sterile, or

- If they are of childbearing potential, agree to practice 2 effective methods of
contraception, at the same time, from the time of signing the informed consent
form through 3 months after the last dose of study drug, or agree to completely
abstain from heterosexual intercourse.

Male patients, even if surgically sterilized (ie, status postvasectomy), who:

- Agree to practice effective barrier contraception during the entire study drug
treatment period and through 3 months after the last dose of TAK-701, or

- Agree to completely abstain from heterosexual intercourse.

6. Voluntary written consent must be given before performance of any study-related
procedure not part of standard medical care, with the understanding that consent may
be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria:

1. Female patients who are lactating or have a positive serum pregnancy test during the
screening period.

2. Major surgery within 14 days before the first dose of TAK-701 or any
planned/anticipated surgery during the study period.

3. Positive test for Hepatitis B or C infection.

4. Active alcohol abuse

5. Active infection requiring systemic therapy, or other serious infection.

6. Antineoplastic therapy (including unconjugated therapeutic antibodies and toxin
immunoconjugates) or any experimental therapy within 21 days before the first dose of
TAK-701.

7. Radiotherapy within 21 days before the first dose of TAK-701.

8. Nitrosoureas or mitomycin-C within 6 weeks before the first dose of TAK-701.

9. Autologous stem cell transplant within 3 months before the first dose of TAK-701, or
prior allogeneic stem cell transplant at any time.

10. Any prior exposure to anti-HGF therapy (eg, AMG-102, AV-299).

11. The patient has symptomatic brain metastasis.

12. Absolute neutrophil count < 1,500/mm3; platelet count < 100,000/mm3.

13. Calculated creatinine clearance < 50mL/minute

14. Any of the following clinical laboratory results during screening (ie, within 28 days
before the first dose of TAK-701):

- Bilirubin > 1.5 times the upper limit of the normal range (ULN).

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times
the ULN. AST and ALT may be elevated up to 5 times the ULN if their elevation
can be reasonably ascribed to the presence of metastatic disease to liver and/or
to bone.

15. Known human immunodeficiency virus (HIV) positive.

16. Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

17. Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias,
congestive heart failure, angina, or myocardial infarction within the past 6 months.

18. Patients having QTc > 470 msec on a 12-lead ECG obtained within 28 days before first
study drug administration.

19. Presence of serious or nonhealing wound, ulcer or bone fracture.